Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary central nervous system lymphoma.

Jennifer I Stern1, Jeffrey J Raizer

  • 1Department of Neurology, Feinberg School of Medicine, Northwestern University, 710 North Lake Shore Dr., Chicago, IL 60611, USA.

Expert Review of Neurotherapeutics
|November 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pembrolizumab, Temozolomide and HSPPC-96 Vaccine in Newly Diagnosed Glioblastoma Post-Chemoradiation: Results from a Multi-institutional, Phase 2, Randomized, Placebo-Controlled Trial.

medRxiv : the preprint server for health sciences·2026
Same author

Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trial.

Neuro-oncology advances·2026
Same author

Cognitive Dysfunction in Migraine: Underlying Mechanisms and Clinical Implications.

Current pain and headache reports·2026
Same author

Medical management of refractory trigeminal neuralgia.

Current opinion in neurology·2026
Same author

A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.

Journal of neuro-oncology·2026
Same author

Mobile App-Based Interactive Care Plan for Migraine: Survey Study of Usability and Improvement Opportunities.

JMIR formative research·2025
Same journal

An overview of the safety and efficacy of sphenopalatine ganglion stimulation for the treatment of chronic cluster headache.

Expert review of neurotherapeutics·2026
Same journal

Multiomics and proteomic insights into Alzheimer's disease biology in Down syndrome.

Expert review of neurotherapeutics·2026
Same journal

Remote deep brain stimulation programming in childhood dystonia: opportunities, challenges, and future directions.

Expert review of neurotherapeutics·2026
Same journal

The differential diagnosis of astrocytic neoplasms and its impact on treatment and prognosis.

Expert review of neurotherapeutics·2026
Same journal

Corticosteroids in withdrawal therapy following medication-overuse headache: a systematic review.

Expert review of neurotherapeutics·2026
Same journal

Clinical efficacy of lacosamide in neuropathic pain: a systematic review of randomized controlled trials.

Expert review of neurotherapeutics·2026
See all related articles

Primary central nervous system lymphoma (PCNSL) is a rare cancer affecting the brain. While treatments improve survival, high rates of relapse and neurotoxicity necessitate exploring new therapeutic strategies.

Area of Science:

  • Neurology
  • Oncology
  • Immunology

Background:

  • Primary central nervous system lymphoma (PCNSL) is a non-Hodgkin's lymphoma exclusively affecting the central nervous system.
  • It occurs in both immunocompetent and immunodeficient individuals, with Epstein-Barr virus association in the latter.
  • PCNSL can involve the brain, leptomeninges, spinal cord, and eyes.

Purpose of the Study:

  • To summarize current understanding and treatment approaches for primary central nervous system lymphoma.
  • To highlight challenges in PCNSL management, including relapse rates and treatment-related toxicities.
  • To discuss emerging therapeutic strategies and the ongoing search for optimal treatment regimens.

Main Methods:

  • Review of existing literature on PCNSL diagnosis and treatment.

Related Experiment Videos

  • Analysis of outcomes associated with methotrexate-based chemotherapy and radiation therapy.
  • Examination of recent advancements including immunotherapy and stem-cell transplantation.

    • Main Results:

    • High-dose methotrexate and whole-brain radiation have improved survival but cause significant neurotoxicity in older patients.
    • Despite current treatments, approximately 50% of patients experience disease relapse.
    • Novel approaches like rituximab, stem-cell transplantation, and radiation-sparing regimens are under investigation.

    Conclusions:

    • Current treatments for PCNSL offer survival benefits but are limited by relapse and neurotoxicity.
    • The optimal treatment strategy for PCNSL remains undetermined, particularly in elderly patients.
    • Ongoing research focuses on refining existing therapies and exploring novel agents to improve outcomes and reduce side effects.